Literature DB >> 22929454

Asymptomatic atrophy of the temporal median raphe of the retina associated with cerebral vasculopathy in homozygous sickle cell disease.

Matthieu P Robert1, Isabelle Ingster-Moati, Olivier Roche, Nathalie Boddaert, Mariane de Montalembert, Valentine Brousse, Manoelle Kossorotoff, Jean-Louis Dufier, Céline Faure.   

Abstract

A 13-year-old girl with homozygous sickle cell disease was referred for vision loss in her left eye of 1 year's duration. Clinical findings were consistent with a past retinal arterial occlusion. In the asymptomatic right eye, spectral domain optical coherence tomography showed a severe atrophy of the inner retinal layers of the temporal median raphe; a significant internal carotid stenosis was also present. We hypothesize that specific atrophy of the retinal temporal median raphe resulted from chronic ischemia. The inner layers of the retina are vascularized by terminal vessels and the median raphe can therefore be regarded as a junction territory; its atrophy may represent an ocular equivalent of a silent border zone cerebral infarct.
Copyright © 2012 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22929454     DOI: 10.1016/j.jaapos.2012.03.006

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  2 in total

1.  Visual Function in Asymptomatic Patients With Homozygous Sickle Cell Disease and Temporal Macular Atrophy.

Authors:  Gilles C Martin; Charlotte Dénier; Olivia Zambrowski; David Grévent; Lenaïc Bruère; Valentine Brousse; Mariane de Montalembert; Dominique Brémond-Gignac; Matthieu P Robert
Journal:  JAMA Ophthalmol       Date:  2017-10-01       Impact factor: 7.389

2.  Monitoring retinal pathology and cerebral injury in sickle cell disease using spectral-domain optical coherence tomography in pediatric patients.

Authors:  Jing Jin; Vinay Kandula; Robin E Miller
Journal:  Pediatr Blood Cancer       Date:  2021-03-31       Impact factor: 3.838

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.